Coronary Heart Disease in Women With Diabetes
- Glory Koerbel, RN, MSN, CDE and
- Mary Korytkowski, MD
Abstract
In Brief
The increased risk for coronary heart disease in women with either type 1 or type 2 diabetes has been well documented. Interventions directed towards primary, secondary, and tertiary prevention should be promptly implemented in these women to improve long-term outcomes.
Footnotes
-
Glory Koerbel, RN, MSN, CDE, is a research nurse coordinator in the Department of Medicine, Division of Endocrinology, at the University of Pittsburgh in Pittsburgh, Pa. Mary Korytkowski, MD, is a professor of medicine in the same department and is also medical director of the University of Pittsburgh Center for Diabetes and Endocrinology in Pittsburgh, Pa.
-
Note of disclosure: Dr. Korytkowski has received honoraria for speaking engagements from Pfizer, Inc., and Bristol Myers Squibb, both of which are makers of lipid-lowering pharmaceutical agents. She has received funding to conduct research on estrogen therapy in women with diabetes from Wyeth Ayerst Corporation, makers of estrogen pharmaceutical products.
- American Diabetes Association
